1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Oncology Market Access Europe – Payer and Industry Perspectives




Oncology Market Access Europe – Payer and Industry Perspectives answers your questions:

What are payers looking for when making decisions regarding oncology reimbursement?
How are HTAs and other challenges affecting market access and what insight do payers offer?
How do payer decisions vary from market to market and what factors influence those decisions?
What will be the future role of real world data in payer decision-making?
What role do risk-sharing schemes, expanded access programmes and other pricing schemes play?
What factors should companies take into account when planning market access strategies?
Which innovations, such as PD-1 inhibitors, vaccines, personalised medicine and companion diagnostics show the most promise?



Oncology market access faces significant and mounting challenges as payers increase data requirements and financial austerity holds sway over decision-making. As pricing and reimbursement requirements become more stringent, issues of development cost, risk and slow market growth are at the forefront. In order to achieve market access success, companies need to adapt their approach and include health outcomes data to meet payer requirements.

Critical insight

Based on interviews and surveys with experts from the UK, Germany, Italy, France and Spain, FirstWord’s Oncology Market Access Europe – Payer and Industry Perspectives lays out the current – and growing – challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging from changing payer data requirements and financial austerity to the adoption of formalised HTA, the report offers critical strategies, knowledge and a roadmap to the future.

A report for the whole industry

The challenges for oncology market access are expected to increase and grow in the near future, making Oncology Market Access Europe – Payer and Industry Perspectives a must-read report not only for those working in market access, brand strategy, business development and licensing, but in biosimilars, payer relationships and drug innovation.










Key benefits, features and insights

Oncology market access is evolving and requires constant updates to keep abreast of changes. In this report, stakeholders will:

Gain insight into both the industry and payer perspectives, with particular reference to the increasing importance of robust clinical health outcomes data
Understand the key issues affecting access and how they vary between markets
Learn about key strategies for success, such as patient access schemes, price-volume agreements and price capping
Identify what effective strategies are used by which companies and why they work
Understand why the industry needs to adapt to an evolving and challenging landscape
Gain insight into how market access issues are driving decisions around R&D

Key Features

Insight into the innovative strategies being employed to gain market access
Overview of new drug approvals and oncology pipeline prospects such as cancer vaccines, niche indications and personalised medicine
Examination of the role of HTAs from both payer and industry perspectives
Key findings regarding the importance of early inclusion of market access considerations

Key Insights

How oncology market access varies from country to country and why
Complete overview of current oncology market access trends and challenges
The payer perspective on everything from transparency in information to the use of health outcomes data in decision making
How payers view the HTA process and its role in the short to medium term



Key experts interviewed


UK payer: Deputy Head of Medicines Management for a PCT with regional and local funding and budgetary decision making responsibility
German payer: Head of a national budgetary committee with national, regional and local funding and budgetary decision making responsibility
Italian payer: Pharmacist involved in purchasing of drugs and devices for hospital and with national, regional and local funding and budgetary decision making responsibility
Spanish payer: Professor of health economics and advisor to the Ministry of Health on pricing and reimbursement issues, with national, regional and local funding and budgetary decision making responsibility
French payer – Hospital pharmacist involved in buying medical products including drugs and medical devices for a group of nine hospitals with regional and local funding and budgetary decision making responsibility
Former oncology marketing manager, BMS
Oncology marketing manager, GSK
Oncology medical manager, GSK
Oncology market access, Pfizer




Table Of Contents

Oncology Market Access Europe - Payer and Industry Perspectives
1.Executive summary
1.2.Innovation has changed the course of the disease
1.3.The cost of treating cancer is expected to continue to rise
1.4.Innovative strategies for obtaining oncology market access are being employed
1.5.The challenges are expected to continue to grow - and with it, the importance of
a robust oncology market access strategy
2.Research objectives and methodology
3.Introduction.
3.1.Oncology market access is different for a variety of reasons
3.2.Despite the challenges, oncology market access is being achieved in many cases
4.Oncology market dynamics
4.1.Although a commercially significant sector, oncology has experienced a slowing
in growth in recent years
4.2.A number of new oncology drugs were approved in 2013
4.3.The current oncology pipeline is wide and varied - and offers some interesting prospects
4.4.The oncology market is dominated by several leading companies -
but there are many others with one or two key products
4.4.1.Roche - the market leader and oncology innovator
4.4.2.Novartis is re-establishing its oncology presence through acquisition
4.4.3.Pfizer is growing its portfolio through acquisition and targeted research
4.4.4.BMS is experiencing ongoing growth in oncology and has a promising pipeline
4.4.5.There are several smaller players with one or two key oncology drugs
4.5.Cancer vaccines, niche indications and personalised therapies are expected to
drive the oncology market in the near future
5.Market access in oncology
5.1.Obtaining market access for oncology drugs varies across different markets
5.2.What are the key challenges for oncology market access?
5.2.1.The payer perspective
5.2.2.The industry perspective
5.2.3.Different cancers present different challenges
5.2.4.Obtaining access in certain markets can be more difficult
5.2.5.The challenges are expected to become more difficult in the short to medium term
5.2.5.1.The industry perspective
5.2.5.2.The payer perspective
5.3.Current trends in oncology market access
5.3.1.Value, rather than cost, is increasingly driving decision making
5.3.2.The pharmaceutical industry is seeking to define value -
but payers are not necessarily looking at it the same way
5.4.HTAs are currently widely used in certain markets but they are not expected to
be implemented in those markets where they are not undertaken
5.5.The payer perspective
5.6.The industry perspective
5.7.Market access considerations are driving RandD decision making for some companies
5.8.The industry perspective
5.9.The payer perspective
6.Strategies for effective oncology market access
6.1.There are several strategies that can be employed to ensure market access is attainable
6.1.2.Risk-sharing schemes have been used with varying success
6.1.3.The payer perspective
6.1.4.The industry perspective
6.1.5.Patient access schemes can be used to help boost market access;
however, the right scheme must be adopted in order to provide benefit
6.1.6. Pricing schemes are relatively unusual, although informal discounts will be
given on an individual basis
6.1.6.1. Launch sequencing can be used as a pricing tool to affect access
6.1.7.Including market access as a key element of commercial strategy is key to
market access success
6.1.7.1.Early inclusion of market access considerations in the development process
is vital for success at launch
6.1.7.2.The industry perspective.
6.1.7.3.The payer perspective
6.1.7.4.Payers need robust clinical and economic data to make their decisions
6.2.Early engagement with payers is critical to ensure awareness of a new
oncology drug and its potential budgetary impact
6.2.1.The industry perspective
6.2.2.The payer perspective
6.2.3.Payers are looking for open and honest communications on a regular basis
6.3.Advocacy can be a key aspect of obtaining market access, and this is
expected to become increasingly the case
7.Contributors

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.